Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy

EGF receptor (EGFR)–targeted monoclonal antibodies (mAb), such as cetuximab, execute their antitumor effect in vivo via blockade of receptor–ligand interactions and engagement of Fcγ receptors on immune effector cells that trigger antibody-dependent cell-mediated cytotoxicity (ADCC). We show that tu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Bedi, Atul, Chang, Xiaofei, Noonan, Kimberly, Pham, Vui, Bedi, Rishi, Fertig, Elana J., Considine, Michael, Califano, Joseph A., Borrello, Ivan, Chung, Christine H., Sidransky, David, Ravi, Rajani
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3640459/
https://ncbi.nlm.nih.gov/pubmed/22927667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0101-T
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items